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Abstract—Hyperglycaemia in critically ill patients increases the 
risk of further complications and mortality. A long-term 
verification of a model that captures the essential glucose- and 
insulin-kinetics is presented, using retrospective data gathered 
in an Intensive Care Unit (ICU). The model uses only two 
patient specific parameters, for glucose clearance and insulin 
sensitivity. The optimization of these parameters is 
accomplished through a novel integration-based fitting 
approach, and a piecewise linearization of the parameters. This 
approach reduces the non-linear, non-convex optimization 
problem to a simple linear equation system. The method was 
tested on long-term blood glucose recordings from 17 ICU-
patients, resulting in an average error of 7%, which is in the 
range of the sensor error. One-hour predictions of blood 
glucose data proved acceptable with an error range between 7-
11%. These results verify the model’s ability to capture long-
term observed glucose-insulin dynamics in hyperglycaemic 
ICU patients. 
 
Keywords—Critical Care, Glucose, Hyperglycemia, 
Insulin, Modeling. 
 
 
I.  INTRODUCTION 
 
Critically ill patients often experience stress-induced 
hyperglycemia and high levels of insulin resistance, even if 
they have no history of diabetes [1-3]. Hyperglycemia can 
lead to an increased risk of further complications such as 
severe infections, myocardial infarctions, polyneuropathy 
and multiple organ failure [1, 4, 5]. Tight glucose control 
has been shown to reduce intensive care unit (ICU) patient 
mortality by as much as 45% [1]. To automate blood 
glucose management, models of insulin- and glucose-
kinetics are required that are capable of capturing long-term 
dynamics in a physiological realistic way. A new, 
physiologically verified model [6] and novel integration-
based fitting method are presented to evaluate the validity of 
the model over long periods using retrospective clinical 
data. 
 
 
II.  METHODOLOGY 
 
A. Model 
 
The basis for the presented model is the 3-compartment 
Minimal Model proposed by Bergman [7]. It was reduced to 
2 compartments [8] and enhanced by additional dynamics 
[6, 9]. These additional dynamics account for an 
accumulation dynamic of insulin [10, 11], non-linear 
saturation of exogenous insulin appearance [12], and 
saturation of insulin utilisation and glucose clearance [13, 
14]. To reduce model complexity and better match known 
physiological response, a term was included to suppress 
endogenous insulin secretion during periods of high 
exogenous insulin infusion [15]. The resulting model is 
defined: 
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where G = concentration of the plasma glucose above the 
basal level (mmol/L), GE = equilibrium level for plasma 
glucose concentration (mmol/L), I = concentration of the 
plasma insulin above basal level (mU/L), IB = basal level for 
plasma insulin concentration (mU/L), P(t) = exogenous 
glucose infusion rate (mmol/(L·min)), u(t) = insulin infusion 
rate (mU/min), VI = assumed insulin distribution volume 
(L), n = delay in interstitial transfer of insulin (min-1), pG = 
fractional clearance of plasma glucose at basal insulin(min-1) 
– time varying, SI = insulin sensitivity (L/mU·min) – time 
varying, k = parameter controlling the effective half life of 
insulin (min-1),   I = Michaelis-Menten parameter for insulin 
saturation,   G = Michaelis-Menten parameter for glucose 
clearance saturation (L/mU). 
This model has been physiologically verified over short 
5 hour clinical trials for adaptive, targeted glucose control 
[6, 9]. 
 
B. Parameter Fitting and Identification 
 
The objectives for the fitting method are low 
computation time, high accuracy for tracking changes in 
time varying patient specific parameters (pG, SI) and 
physiologically realistic values of optimised parameters. A 
method that is convex and not dependent on starting points, 
as with non-linear recursive least squares (NRLS) [16], is 
also desirable. 
Generic parameters (VI = 12 L, n = 0.16 min-1, k = 
0.0099 min-1,   G = 0.04 L/mU,   I = 0.0017 L/mU) were 
found through extensive literature research [6] and are 
assumed to be constant. The exogenous feed details, P(t), 
are known for each patient. The equilibrium glucose level, 
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GE, can be estimated by averaging the glucose readings 
across the prior 12 hours.  
To identify pG and SI, the L2 norm between the 
measured data and the model output is minimized. 
Integration of (3) and substitution of the total measured 
glucose level GT=(G+GE) and insulin saturation term 
)1( QQQ Gα+= delivers the following expression: 
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To reduce computational complexity and account for a 
variation over time, the total time interval is divided into 
equal segments during which pG and SI are held constant, 
and are defined using heavyside step functions, H(t). 
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The only unknown parameters in (4), pGi and SIi, are 
now constant over these time intervals and can be written in 
a simple linear equation system. The number of equations 
for each time segment can be arbitrarily selected: 
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To make sure both pG and SI are within physiologically 
valid ranges, weighted constraints are placed on both 
parameters when solving (7). 
To best compute the integrals in (4), the profile of GT is 
approximated using simple linear interpolation between the 
data points, forming a piecewise linear curve GT-approx. The 
error between the patient’s real glucose level GT-real and the 
approximated curve GT-approx is ε: 
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Using (4), GT-real can be calculated in any given time 
interval [t0,t1] with the constant parameters Gp and IS : 
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Where the error term E(t) is defined: 
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Comparing the patient specific error terms to the 
corresponding integral terms from (9) shows that the error is 
small and the approximated curve does not compromise the 
quality of the optimisation utilising integral functions. 
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Thus, for a general time period [t0,t] the approximation 
GT-approx can be used to represent the real data between 
measurements with no significant error as long as blood 
glucose levels are GT-real(t)>1, which is always true in 
hyperglycemia. 
Integral functions also have the advantage of being 
insensitive to noise in the measured glucose data, effectively 
providing a low-pass filter in the summations involved in 
numerical integration.  
 
 
III.  RESULTS 
 
For the long term data fitting and model verification, a 
random selection of 17 patients from a 201 patient data audit 
[6] with a period greater than one day and intervals between 
measured data points of three hours or less, were used. The 
data density of three hours was selected to ensure enough 
measurements to enable a good model evaluation.  The 
entire length of stay was not always considered, as many 
patients only had a shorter period of data that fitted the 
criteria. This subset broadly represents the cross section of 
patients seen in the ICU, regarding medical condition, age, 
sex, APACHE II scores and mortality.  
Two of these fits are shown in Fig. 1 and Fig. 2. To 
further reduce the noise in the data and the possibility of 
erroneous measurements, the fitted values of pG and SI were 
replaced by their smoothed 3-point moving average to 
produce the model curve in each figure. 
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Patient 1090 had the lowest fitting error and standard 
deviation of the 17 patients considered, representing the best 
overall fit.  Over the 1.6 days of the patient’s 7-day stay, the 
insulin infused was constant at 1 U/hr, and the feed was 
constant at 0.0247 mol/(L·min). Figure 1 shows a relatively 
constant normoglycemic profile over this time with low 
variations in insulin sensitivity, SI, showing that the patient 
was very stable. The parameter pG was effectively constant 
at 0.02 min-1 where SI still shows some diurnal variation. 
Patient 87 had a length of stay of 35 days, and over six 
consecutive days had sufficient data measurements for 
model fitting.  Unlike patient 1090, the glucose level is 
much more variable, as is the insulin sensitivity, SI.  The 
glucose clearance, pG, is stable over the time considered at 
0.01 min-1, but does reach values of up to 0.015 min-1 on 
different days. These values are well within the 
physiological range expressed in the literature [13, 17-19], 
 
 
Fig. 1.  Patient 1090 blood glucose data fit (top) and corresponding 
insulin sensitivity parameter SI (bottom). 
 
 
Fig. 1.  Patient 87 blood glucose data fit (top) and corresponding 
insulin sensitivity parameter SI (bottom). 
 
and show a change in the metabolic responses at these time 
periods.  Over the six days, the insulin infusion and glucose 
feed varied significantly as well. 
To measure the error in data fitting, the “chi-square” 
quantity is calculated for the boundaries of the range of 
glucose measurement error (3.5-7%) [20]. This reflects an 
error in the data fitting similar to the measurement error 
used in NRLS fitting [21]. The expected value of χ2 is   =N-
M where N is the number of measurements and M=2 the 
number of parameters. The results are given in Table I. 
The average value of ν lies between χ23.5  and χ27, 
corresponding to a measurement error of 4.79%, which is in 
the range of the reported sensor measurement error. The 
average verification interval was 3.1 days, with the longest 
at 12.3 days. The average fitting error over all patients was 
4.39%, with a range of  1.03-7.62%. These values are also 
within the experimental error. 
To test the prediction capability of the model, data from 
three patients who had a number of measurements one hour 
apart, was used. The fit from the previous eight hours was 
used and the parameters pG, SI and GE were held constant 
over the next hour. The predicted value was then compared 
to the actual data, giving the percentage error e. This process 
was then repeated in moving 9 hour blocks for 15-25 
Predictions per patient. The results in Table II show that 
one-hour predictions are on average 7-11% in error, which is 
also close to the measurement error. 
 
TABLE I 
ERRORS IN DATA FITTING 
 
Patient 
Number 
Time 
interval 
(days) 
2
5.3χ  27χ  
 
ν  
     
24 2.0 57.82 14.46 29 
87 6.4 21.73 5.43 45 
130 1.4 142.20 35.55 28 
229 10.0 213.64 53.41 75 
289 1.7 49.52 12.38 10 
468 1.7 13.13 3.28 14 
484 1.7 8.88 2.22 15 
486 1.6 12.30 3.076 13 
519 12.3 62.73 15.68 79 
554 2.3 87.42 21.85 37 
666 1.6 15.48 3.87 12 
847 1.5 19.67 4.92 9 
1016 1.6 16.55 4.14 10 
1025 1.7 20.74 5.19 12 
1090 1.6 0.78 0.19 7 
1099 1.6 23.44 5.86 11 
1125 1.7 10.64 2.66 8 
     
Average 3.1 45.69 11.42 24.35 
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TABLE II 
MODEL PREDICTION ERRORS 
 
Patient Avg. prediction 
error e [%] 
Error standard 
deviation [%] 
24 6.77 4.68 
130 10.92 10.02 
554 10.73 9.79 
 
 
IV.  DISCUSSION 
 
The fitting method proves to be very effective in 
reducing the non-linear, non-convex optimization problem 
to a simple linear equation system, which is not starting 
point dependent. By constraining the parameter optimization 
to physiologically valid ranges, the resulting values for pG 
and SI are valid. The glucose clearance pG remained nearly 
constant throughout all patients, while SI showed a greater 
variation, which matches reported physiological behavior 
[22]. The average fitting error is in the range of the 
measurement error of the sensor and matches the expected 
χ
2
 value. The low long-term-fit error values validate the 
models ability to capture the highly variable dynamics of 
hyperglycemic ICU patients over long periods. 
The prediction of the glucose values for a period of one 
hour ahead were within 7-11% of the actual value, further 
validating the pG and SI values. Note that holding these 
parameters constant during the prediction interval is a 
conservative choice, as it ignores the prior changes in value. 
 
 
V.  CONCLUSION 
 
The parameter identification method shows promise for 
similar drug therapy models and control algorithms. The 
optimized model was able to capture the dynamics in the 
measured data to within the 7% measurement error of the 
sensor, and was tested for time periods up to two weeks. The 
model provides a prediction for one hour with an error 
between 7-11%, which is acceptable for control applications 
in a clinical setting. Due to the low computational 
complexity of the optimization algorithm, it is also well 
suited for real-time clinical control applications. 
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